Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Larimar Therapeutics, Inc.LRMR · Entity 5634 | Director · President and CEO | January 26, 2026 | January 27, 2026 |
| Teligent, Inc.TLGT · Entity 134764 | Director | July 21, 2021 | July 22, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Larimar Therapeutics, Inc.
Report date January 26, 2026 · Filed January 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 368,276 |
Reported balance
After 2026-01-26 transaction · row 1
1 source rowRow 1 · 2026-01-26 · Grant · Acquired 100,100 · Balance 368,276 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.60 · Expires 2036-01-26 | Direct | 600,600 |
Reported balance
After 2026-01-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-01-26 · Grant · Acquired 600,600 · Balance 600,600 F7: The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 31,155 |
Reported balance
Holding disclosure · report date 2026-01-26 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 31,155 F2: Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Meadow Lainey Ben-Maimon ("Meadow Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Meadow Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 31,155 |
Reported balance
Holding disclosure · report date 2026-01-26 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 31,155 F3: Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Olivia Liat Stein ("Olivia Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Olivia Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 31,156 |
Reported balance
Holding disclosure · report date 2026-01-26 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 31,156 F4: Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Ella Bar Stein ("Ella Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Ella Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 31,156 |
Reported balance
Holding disclosure · report date 2026-01-26 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 31,156 F5: Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Romi Aleeza Stein ("Romi Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Romi Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy Trust | 31,156 |
Reported balance
Holding disclosure · report date 2026-01-26 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 31,156 F6: Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Matzi Mark Ben-Maimon ("Matzi Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Matzi Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F2: Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Meadow Lainey Ben-Maimon ("Meadow Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Meadow Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
F3: Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Olivia Liat Stein ("Olivia Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Olivia Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
F4: Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Ella Bar Stein ("Ella Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Ella Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
F5: Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Romi Aleeza Stein ("Romi Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Romi Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
F6: Represents shares held by the Irrevocable Deed of Trust of Carole S. Ben-Maimon for the Benefit of Matzi Mark Ben-Maimon ("Matzi Trust"), of which the Reporting Person serves as trustee. The Reporting Person disclaims Section 16 beneficial ownership of the shares held by the Matzi Trust except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed to be an admission that she has beneficial ownership of such shares for Section 16 or any other purpose.
F7: The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.
Teligent, Inc.
Report date July 21, 2021 · Filed July 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 150,000 |
Reported balance
After 2021-07-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-07-21 · Grant · Acquired 150,000 · Balance 150,000 F1: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock F3: Each non-employee director of the Issuer is entitled to receive an annual grant of restricted stock units ("RSUs") with a value of $75,000 on the date of grant, such grants to be effective as of the date of the 2021 annual meeting of stockholders, and annually thereafter. The closing price of the Issuer's common stock on the date of grant was $0.50. F2: The shares underlying the derivative securities shall vest fully on the first anniversary of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock
F2: The shares underlying the derivative securities shall vest fully on the first anniversary of grant.
F3: Each non-employee director of the Issuer is entitled to receive an annual grant of restricted stock units ("RSUs") with a value of $75,000 on the date of grant, such grants to be effective as of the date of the 2021 annual meeting of stockholders, and annually thereafter. The closing price of the Issuer's common stock on the date of grant was $0.50.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 26, 2026 Filed Jan 27, 2026 22:04 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 600,600 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001193125-26-024826 · ownership.xml · derivative · entry 7 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 600,600 Underlying: Common Stock · 600,600 shares Expires 2036-01-26 F7 · derivative.exercise_date: The option vests 25% on January 26, 2027, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 22:04 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantCommon Stock | 100,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-024826 · ownership.xml · nonDerivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 368,276 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:15 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 546,000 | $0.00 Strike: $3.46 | $0.00 |
DisclosureSEC source: 0001062993-25-001078 · form4.xml · derivative · entry 5 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 546,000 Underlying: Common Stock · 546,000 shares Expires 2035-01-22 F5 · derivative.exercise_date: The option vests 25% on January 22, 2026, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 22, 2025 Filed Jan 24, 2025 21:15 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantCommon Stock | 91,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-001078 · form4.xml · nonDerivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 387,208 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 21:31 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 396,750 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0001062993-24-001083 · form4.xml · derivative · entry 2 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 396,750 Underlying: Common Stock · 396,750 shares Expires 2034-01-17 F2 · derivative.exercise_date: The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 17, 2024 Filed Jan 19, 2024 21:31 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantCommon Stock | 66,125 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-001083 · form4.xml · nonDerivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,954 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Read SEC document |
| May 17, 2023 Filed May 18, 2023 18:13 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | PurchaseCommon Stock | 5,000 | $3.71 | $18,525.00 |
DisclosureSEC source: 0001062993-23-011546 · form4.xml · nonDerivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 266,829 Read SEC document |
| January 31, 2023 Filed Feb 3, 2023 01:15 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 325,000 | $0.00 Strike: $4.94 | $0.00 |
DisclosureSEC source: 0000899243-23-003734 · doc4.xml · derivative · entry 2 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2033-01-31 F2 · derivative.exercise_date: The option vests 25% on January 31, 2024, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| January 31, 2023 Filed Feb 3, 2023 01:15 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantCommon Stock | 205,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-003734 · doc4.xml · nonDerivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,829 F1 · shares: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. Read SEC document |
| September 16, 2022 Filed Sep 19, 2022 11:00 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | PurchaseCommon Stock | 31,746 | $3.15 | $99,999.90 |
DisclosureSEC source: 0001062993-22-019645 · form4.xml · nonDerivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,829 F1 · shares: Represents shares of common stock purchased in the underwritten offering of Larimar Therapeutics, Inc. at the offering price, which closed on September 16, 2022. Read SEC document |
| May 10, 2022 Filed May 13, 2022 00:28 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $2.92 | $0.00 |
DisclosureSEC source: 0001062993-22-012309 · form4.xml · derivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2032-05-10 F1 · derivative.exercise_date: The option vests 25% on May 10, 2023, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting dates. Read SEC document |
| January 18, 2022 Filed Jan 21, 2022 00:16 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 182,000 | $0.00 Strike: $8.75 | $0.00 |
DisclosureSEC source: 0001062993-22-001319 · form4.xml · derivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,000 Underlying: Common Stock · 182,000 shares Expires 2032-01-18 F1 · derivative.exercise_date: The option vests 25% on January 18, 2023, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date. Read SEC document |
| July 21, 2021 Filed Jul 22, 2021 17:04 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantRestricted Stock Units · Derivative | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-21-094965 · tm2123025d3_4.xml · derivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock F3 · price: Each non-employee director of the Issuer is entitled to receive an annual grant of restricted stock units ("RSUs") with a value of $75,000 on the date of grant, such grants to be effective as of the date of the 2021 annual meeting of stockholders, and annually thereafter. The closing price of the Issuer's common stock on the date of grant was $0.50. F2 · derivative.exercise_date: The shares underlying the derivative securities shall vest fully on the first anniversary of grant. F2 · derivative.expiration_date: The shares underlying the derivative securities shall vest fully on the first anniversary of grant. Read SEC document |
| January 19, 2021 Filed Jan 21, 2021 15:56 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (Right to Buy) · Derivative | 106,700 | $0.00 Strike: $19.61 | $0.00 |
DisclosureSEC source: 0001192482-21-000075 · edgar.xml · derivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,700 Underlying: Common Stock · 106,700 shares Expires 2031-01-19 F1 · derivative.exercise_date: The option vests 25% on January 19, 2022, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued employment with the Issuer through the applicable vesting date. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 11:09 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantStock Option · Derivative | 2,000 | $0.00 Strike: $0.74 | $0.00 |
DisclosureSEC source: 0000352998-21-000004 · primary_doc.xml · derivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires 2031-01-04 F2 · price: These securities were granted as part of the Issuer's equity compensation to its non-employee directors. F1 · derivative.exercise_date: These securities vest fully 12 months from the date of grant. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 17:50 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | GrantStock Option (right to buy) · Derivative | 411,400 | $0.00 Strike: $11.90 | $0.00 |
DisclosureSEC source: 0001192482-20-000736 · edgar.xml · derivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 411,400 Underlying: Common Stock · 411,400 shares Expires 2030-07-16 F1 · derivative.exercise_date: The Option was granted on July 16, 2020 subject to stockholder approval, which was obtained at the Company's special meeting of stockholders on September 29, 2020. The Option vests 25% on July 16, 2021, with the remaining 75% vesting in equal monthly installments over 36 months, subject to the Reporting Person's continued service with the Issuer through each applicable vesting date. Read SEC document |
| June 26, 2020 Filed Jun 30, 2020 21:00 UTC | Larimar Therapeutics, Inc. LRMR · Entity 5634 | OtherCommon Stock | 25,083 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000586 · edgar.xml · nonDerivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,083 F1 · kind: Pro rata distribution from Chondrial Therapeutics Holdings, LLC ("Holdings") to its members, for no consideration. The reporting person is a member of the board of managers and President and Chief Executive Officer of Holdings. Read SEC document |
| January 02, 2020 Filed Jan 3, 2020 10:54 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0001104659-20-000634 · tm201128d3_4.xml · derivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2030-01-02 F2 · price: These securities were granted as part of the Issuer's equity compensation to its non-employee directors. F1 · derivative.exercise_date: These securities shall vest fully 12 months from the date of grant. Read SEC document |
| October 02, 2019 Filed Oct 4, 2019 17:54 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantStock Option · Derivative | 10,653 | $0.00 Strike: $0.88 | $0.00 |
DisclosureSEC source: 0001144204-19-047417 · tv530697_form4.xml · derivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,653 Underlying: Common Stock · 10,653 shares Expires 2029-10-02 F1 · security: These securities were issued pursuant to the terms of the Non-employee Directors Compensation Policy as compensation for services provided to the Board for the fourth quarter of 2019. Read SEC document |
| July 01, 2019 Filed Jul 3, 2019 11:49 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantStock Option · Derivative | 15,385 | $0.00 Strike: $0.65 | $0.00 |
DisclosureSEC source: 0001144204-19-033725 · tv524759_form4.xml · derivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,385 Underlying: Common Stock · 15,385 shares Expires 2029-07-01 F1 · security: These securities were issued pursuant to the terms of the Non-employee Directors Compensation Policy as compensation for services provided to the Board for the third quarter of 2019. Read SEC document |
| May 30, 2019 Filed May 31, 2019 10:39 UTC | Teligent, Inc. TLGT · Entity 134764 | PurchaseCommon Stock | 10,000 | $0.59 | $5,885.00 |
DisclosureSEC source: 0001144204-19-029061 · tv522782_form4.xml · nonDerivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $0.5759 to $0.5898, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| May 13, 2019 Filed May 15, 2019 18:24 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantStock Option · Derivative | 11,628 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001144204-19-026693 · tv521755_form4.xml · derivative · entry 2 BEN-MAIMON CAROLE · CIK 0001529611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,628 Underlying: Common Stock · 11,628 shares Expires 2029-05-13 F2 · security: These securities were issued pursuant to the terms of the Non-employee Director Compensation Policy as compensation for services provided to the Board in the second quarter of 2019. Read SEC document |
| May 13, 2019 Filed May 15, 2019 18:24 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantStock Option · Derivative | 10,901 | $0.00 Strike: $0.86 | $0.00 |
DisclosureSEC source: 0001144204-19-026693 · tv521755_form4.xml · derivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,901 Underlying: Common Stock · 10,901 shares Expires 2029-05-13 F1 · security: These securities were issued pursuant to the terms of the Non-employee Director Compensation Policy as compensation for services provided to the Board in the first quarter of 2019. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 16:01 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001144204-19-000648 · tv510281_4.xml · derivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2029-01-02 F2 · price: These securities were granted as part of the Issuer's equity compensation to its non-employee directors. F1 · derivative.exercise_date: These securities shall vest fully 12 months from the date of grant. Read SEC document |
| January 02, 2018 Filed Jan 4, 2018 16:19 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $3.85 | $0.00 |
DisclosureSEC source: 0001144204-18-000824 · tv482606_form4.xml · derivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-01-02 F2 · price: These securities were granted as part of the Issuer's equity compensation to its non-employee directors. F1 · derivative.exercise_date: These securities shall vest fully 12 months from the date of grant. Read SEC document |
| November 13, 2017 Filed Nov 13, 2017 17:01 UTC | Teligent, Inc. TLGT · Entity 134764 | PurchaseCommon Stock | 3,600 | $3.48 | $12,538.80 |
DisclosureSEC source: 0001144204-17-058444 · tv479369_form4.xml · nonDerivative · entry 2 BEN-MAIMON CAROLE · CIK 0001529611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| November 13, 2017 Filed Nov 13, 2017 17:01 UTC | Teligent, Inc. TLGT · Entity 134764 | PurchaseCommon Stock | 1,400 | $3.48 | $4,869.76 |
DisclosureSEC source: 0001144204-17-058444 · tv479369_form4.xml · nonDerivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,400 Read SEC document |
| January 03, 2017 Filed Jan 5, 2017 16:12 UTC | Teligent, Inc. TLGT · Entity 134764 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $7.05 | $0.00 |
DisclosureSEC source: 0001144204-17-000867 · v456323_form4.xml · derivative · entry 1 BEN-MAIMON CAROLE · CIK 0001529611 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-01-03 F2 · price: These securities were granted as part of the Issuer's equity compensation to its non-employee directors. F1 · derivative.exercise_date: These securities shall vest fully 12 months from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.